Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year High – Time to Buy?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) reached a new 52-week high on Monday. The company traded as high as $98.49 and last traded at $98.3510, with a volume of 309,132 shares changing hands. The stock had previously closed at $93.86.

Analyst Upgrades and Downgrades

KNSA has been the topic of several recent research reports. Wedbush lifted their target price on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a report on Wednesday, October 28th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 28th. Finally, Citigroup raised their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $100.57.

Kiniksa Pharmaceuticals International Stock Performance

The company has a market capitalization of $7.66 billion, a price-to-earnings ratio of 75.61 and a beta of 0.07. The business has a 50 day moving average price of $80.46 and a 200-day moving average price of $61.36.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The business had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. As a group, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CAO Michael R. Megna sold 36,260 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $94.43, for a total transaction of $3,424,031.80. Following the completion of the sale, the chief accounting officer owned 12,697 shares of the company’s stock, valued at $1,198,977.71. This trade represents a 74.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 220,170 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $93.27, for a total transaction of $20,535,255.90. Following the transaction, the chief executive officer owned 780,037 shares in the company, valued at $72,754,050.99. This represents a 22.01% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 831,022 shares of company stock valued at $77,475,599. 51.98% of the stock is owned by insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several large investors have recently made changes to their positions in KNSA. Allworth Financial LP increased its holdings in shares of Kiniksa Pharmaceuticals International by 42.0% during the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after acquiring an additional 134 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Kiniksa Pharmaceuticals International by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock worth $648,000 after purchasing an additional 209 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 21.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock worth $95,000 after purchasing an additional 223 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock worth $811,000 after purchasing an additional 237 shares in the last quarter. Finally, First Trust Advisors LP grew its position in Kiniksa Pharmaceuticals International by 3.1% in the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock valued at $476,000 after purchasing an additional 293 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally.

Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.

The company also develops investigational therapies for inflammatory and immune-mediated conditions, including treatments that target pathways involved in immune-cell activity.